OC
BMY.RT

Oakworth Capital’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Oakworth Capital’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-13,535
Closed -$9K – 622
2020
Q4 		$9K Buy
13,535
+400
+3% +$852 ﹤0.01% 446
2020
Q3 		$29K Hold
13,135
– – ﹤0.01% 342
2020
Q2 		$47K Buy
13,135
+12,918
+5,953% +$46.6K 0.01% 281
2020
Q1 		$0 Buy
+217
New +$715 ﹤0.01% 578

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Oakworth Capital's BMY.RT Position: Q1 2021 in Review

Oakworth Capital sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 13,535 shares — an estimated $9K sold.

Oakworth Capital first reported a position in BMY.RT in Q1 2020 and held it in 4 quarters. The position peaked at $47K in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Oakworth Capital reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Oakworth Capital sold 13,535 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $9K.
  • Oakworth Capital first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q1 2020 and held it in 4 quarters.
  • Oakworth Capital's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $47K in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Oakworth Capital's 13F filing for Q1 2021, filed 30 Apr 2021.